Eden Research Share Discussion Threads

[attyg] 22/1/2024 12:40

I accept I must eat humble pie - I expected the performance to be much better than reported.

Couple of comments.

I am not overly impressed with product sales of £2.6m - just making the Cavendish forecast - which did not include anything for ecovelex.

Indeed, to trumpet the total revenue of £3.1m as ahead of market expectations by some £300k is somewhat disingenuous when it is highly likely some £305k credited to the revenue was the Deferred Income received from Corteva in 2021 and 2022 (Note 1.4 in last year's accounts). With EA in Italy and the ability to sell ecovelex, it is surely likely all the £305k deferred in 2022 has been released. Indeed, most, if not all, of the remaining £195k recognised in 2023 will be attributed to Corteva.
So, good to have that all released - but no cash impact from the £305k.

What disappoints me most is the silence on the value of the ecovelex sales in 2023.It is even more disappointing that we have silence on the value of orders received. I was expecting the company to have been more transparent about what shareholders might look forward to in 2024.
Due to this - not opaqueness - dark hole from our BoD, Cavendish are unable to make any re-assessment of their 2024 projections or provide any sense of what might be expected in 2025.

I daresay this silence is what Corteva wants - or am I again too prepared to be bullish?
I remain expectant that the Company will gain approval in France for the powdery and downy mildew, if not 2024, then 2025.
I remain bullish on so many aspects of Eden - including Corteva combining our fungicide and nemanticide in their SAT business going forward. Time will tell if Corteva has any rights to the insecticide(s) to further add to their SAT.
I expect insecticide announcements will be delayed - but only because it is so important and thus, competitive?
I expect lots - but I have to resign myself for yet more delays.
I will make money on this - if I live long enough.

I shall hibernate for some time.

[money never sleeps] 22/1/2024 12:24

Erinvale 1
I can well understand investor scepticism, yours included, but let's not forget Eden has always been a small loss making business seeking to navigate a bureaucratic maze not to mention the ever shifting world of politics. I am sure that a huge marketing budget would have helped a lot to drive product sales but it is wholly unrealistic and Eden would already now be bust - just look at what recently happened to AgBiome with all its lay-offs even though it was heavily funded by The Gates Foundation. That company was too bogged down in endless expensive R&D. Eden has come through a whole lot of that and the realistic near term hope is that it will soon be a self-funding company.

The fate of AgBiome might also play directly into Eden's hands given the lucrative cut flower export market from Columbia. AgBiome was tied in with ANASAC to develop, register and commercialize its Howler fungicide, but Eden's deal with ANSAC is more recent than that. The Botrytis field test results also show Mevalone compares very well against the (few) competitor products available or in development. Eden's product seems to be one the best going, if not standout the best, by common consensus. It is no wonder that Eden is gaining commercial traction in its products. That is despite the obvious industry-wide hypocrisy / self-interest with agro-chem companies happily continuing to sell their more harmful traditional products.

I find that "Transformational" is a label oft used by AIM companies in their rns announcements. I suggest it is a favourably loose and useful term of reference favoured by corporate lawyera and NOMADS. DYOR and be your own judge.

[money never sleeps] 22/1/2024 12:00

Z1CO
You can just thank my loyal sockpuppets. I wish to take no credit.

[z1co] 22/1/2024 11:45

KB

Indeed another increase of by at least 50% for this year

[brucie5] 22/1/2024 11:27

Z1CO22 Jan '24 - 10:58 - 16565 of 16568
0 1 0
The big question is how much will it increase again this year ?
--------------------------------------------------------------
Still at EBITDA loss; I wonder if Investing is still of the opinion that it will reach BE this year?

[kittybiscuits] 22/1/2024 11:19

Z1CO,

With Sales for Mevelone essentially starting in California, USA in 2024 (Approval for it was only granted in very early Jan 24'), with that state being bigger than the next 9 states put together, Mevelone sales in the USA should be extensively more in 2024 than 2023.

With the Insecticide product completing hundreds of fields trails in 2023 and a partnership commercial discussions ongoing now and expected to be announced in 2024...

and with approval for Ecovelux only just granted emergency approval in one location in the EU, and potentially other emergency approvals, (or outside change of full-blown EU approval in 2024) and label extension for other seeds

....all would point to revenues being extensively higher in 2024.

[erinvale1] 22/1/2024 11:08

MoneyNS: I was deeply involved with Eden for some years since inception and worked with scientists on Nematodes etc. So, I have some understanding of what the company is about.

Every year, for at least 20, annual reports have told shareholders that the upcoming year will be “transformational”. Their prognostications must therefore be treated with extreme caution.

Eden has excellent products, which have use across the agriculture and wine sectors, but not the slightest idea of how to market them. Their foundational belief is that distribution agreements equate to sales - which, very evidently, they do not.

Eden may indeed achieve its goals , but with the current management in charge, and given that so many have lost money on this underperforming stock, scepticism should be the default attitude.

[z1co] 22/1/2024 10:58

For those that are still thinking about the past have either lost money over the years or are just being sarcastic.

It's the prospects of the company going forward that will drive the share price higher

The revenue for the year just finished increased by 72% and was 11% ahead of expectations.

The big question is how much will it increase again this year ?

[z1co] 22/1/2024 10:52

Money never sleeps , nice summary.

Many thanks.

[supersonico] 22/1/2024 10:12

That's my impression also.

[weyweyumfozo] 22/1/2024 10:11

I seem to recall that Mevalone could be applied as a "preventative" against botrytis in vineyards, before it appears.

Is the same mix of ingredients used in anti botrytis Mevalone as in the proposed anti powdery and downy mildew Mevalone?

If it is, and a vineyard is infected with powdery and downy mildew, could a grower decide to do a "preventative" spray against botrytis, which purely by coincidence of course, would treat powdery and downy mildew, before label extension is granted?

From the RNS:

"There is also the potential to significantly expand the use of Esseva for the treatment of powdery and downy mildews, for which an application was submitted in 2023. It is currently expected that this label expansion application will be granted in 2024, subject to timely approval by the French regulatory authorities."

[swiftnick] 22/1/2024 10:01

Agreed Jonesy. We may even have reached a tipping point.

[jonesy100] 22/1/2024 09:42

Given the atrocious track record of this company on delivering even a hint of commercial success, I thought these results were mildly encouraging.

[alchemy] 22/1/2024 08:55

I've just taken 1.7 to the power of three. Then 4 .I respectfully submit we sre investible

[supersonico] 22/1/2024 07:56

Mevalone ?



Our company is one of the leading full-scale pesticide tollers in Europe. Beside the large multinational manufacturers of original products, among our customers also belong the emerging enterprises dealing with generic products. Our services cover the following areas:

• formulation of plant protection products
• fill & pack of plant protection products
• logistic activities connecting to the products formulated and packed by Chemark Kft.
• development of packaging and formulations
• analytical services linked to the plant protection products
• artwork related services linked to the packaging materials.
Sale of small-pack pesticides on the Hungarian market also belongs to our activities.

AWGATWT

[erinvale1] 22/1/2024 07:38

Usual Eden guff. Promises of future prosperity after almost 30 years of failure. Company milked by overpaid directors who are self-serving and inadequate. There may be hope for the future but on present showing it is far from investible.

[kittybiscuits] 22/1/2024 07:34

“Revenue for the year has increased by approximately 72% to £3.1m (FY2022: £1.8m)

Product sales for the year has increased by approximately 63% to £2.6m (FY2022: £1.6m)”

[supersonico] 22/1/2024 07:07

TRADING UPDATE
EDEN RESEARCH PLC
Released 07:00:07 22 January 2024

[supersonico] 22/1/2024 07:01

Fraudy - Lube tag team - 17 Jun 2022

'A wise person would follow the example of Amati'

[supersonico] 22/1/2024 06:46

SIGNIFICANT SHAREHOLDERS
As of 3 January 2024 significant shareholdings in the share capital of Eden Research plc were:

Amati Global Investors
16,744,070
3.14%
..................................................................

NeutralPOV - 17 Jun 2022 - 15:50:33 - 12335 of 16551 Eden Research - EDEN
ravenna23 17 Jun '22 - 16:10 - 12333
> A wise person would follow the example of Amati, a previous major shareholder, and continually sell down their holding.
> Perhaps Tricky and Fraud have been buying?

Yep, they managed £20 between them.

THE FORGER NeutraIPOV 17 Jun '22 - 16:18 - 12334
> Perhaps they will.

You stupid tw*t, ravenna's reference to "FRAUD" is to YOU.

lol

[supersonico] 22/1/2024 06:38

NUMBER OF AIM SECURITIES IN ISSUE
As of 3 January 2024, the number of shares in issue was 533,352,523.

SIGNIFICANT SHAREHOLDERS
As of 3 January 2024 significant shareholdings in the share capital of Eden Research plc were:

Name

Number of shares

% of the issued ordinary share capital

Hargreaves Lansdown
53,364,313
10.01%

Gresham House Asset Management Limited
52,882,786
9.92%

Octopus Investments
41,551,047
7.79%

Sipcam Oxon S.p.A.
39,285,138
7.37%

Interactive Investor
33,363,457
6.26%

Canaccord Genuity Wealth Management
30,276,307
5.68%

Unicorn Asset Management
23,076,923
4.33%

Rathbones
23,040,287
4.32%

Atul Unadkat
22,099,924
4.14%

JM Finn Nominees Limited
20,147,562
3.78%

Amati Global Investors
16,744,070
3.14%

BGF Investment Management Limited
16,000,576
3.00%

............................

As of 20 July 2023, the number of shares in issue was 381,108,607.

SIGNIFICANT SHAREHOLDERS
As of 20 July 2023 significant shareholdings in the share capital of Eden Research plc were:

Name
Number of shares
% of the issued ordinary share capital

Hargreaves Lansdown
45,307,219
11.89%

Sipcam Oxon S.p.A.
37,614,830
9.87%

Interactive Investor
31,957,945
8.39%

Gresham House Asset Management Limited
27,845,445
7.31%

Canaccord Genuity Group Inc
22,584,000
5.93%

BGF Investment Management Limited
20,233,000
5.31%

JM Finn Nominees Limited
19,635,562
5.15%

Atul Unadkat
18,811,765
4.94%

Rathbone Nominees Limited
13,661,661
3.58%

HSBC Global Custody Nominee (UK) Limited
13,066,384
3.43%

HSDL Stockbrokers
12,436,733
3.26%


Name
Number of shares
% of the issued ordinary share capital

A Abrey
1,620,346
0.43%

L van der Broek
929,500
0.24%

S Smith
911,039
0.24%

R Cridland
130,167
0.03%
...................

NUMBER OF AIM SECURITIES IN ISSUE
As of 21 March 2023, the number of shares in issue was 380,858,607.

SIGNIFICANT SHAREHOLDERS
As of 21 March 2023 significant shareholdings in the share capital of Eden Research plc were:


Name

Number of shares

% of the issued ordinary share capital

BGF Investment Management Limited
51,733,000
13.58%

Sipcam Oxon S.p.A.
37,614,830
9.88%

Hargreaves Lansdown
31,737,596
8.33%

Gresham House Asset Management Limited
27,845,445
7.31%


Interactive Investor
25,172,555
6.61%

Canaccord Genuity Group Inc
22,584,000
5.93%

JM Finn Nominees Limited
19,839,762
5.21%

Atul Unadkat
18,117,567
4.76%

Rathbone Nominees Limited
15,621,872
4.10%

HSBC Global Custody Nominee (UK) Limited
13,066,384
3.43%



Name
Number of shares
% of the issued ordinary share capital

A Abrey
1,620,346
0.43%

L van der Broek
929,500
0.24%

S Smith
911,039
0.24%

R Cridland
130,167
0.03%


SHARES NOT IN PUBLIC HANDS
In the terms of AIM Rules published July 2016 and insofar as it is aware, at 21 March 2023, 31.71% of the Company's AIM securities was not in public hands.

.................................................................................

Atul keeps buying.

As of 30 September 2022, the number of shares in issue was 380,858,607.
As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were:

Number of shares % of the issued ordinary share capital

BGF Investment Management Limited
53,733,000
14.11%

Sipcam Oxon S.p.A.
37,614,830
9.88%

Hargreaves Lansdown
29,839,285
7.83%

Gresham House Asset Management Limited
27,845,445
7.31%


Canaccord Genuity Group Inc
22,584,000
5.93%

Interactive Investor
20,027,730
5.26%

JM Finn Nominees Limited
19,277,362
5.06%

Atul Unadkat
17,545,098
4.61%

Rathbone Nominees Limited
15,708,999
4.12%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.48%


......................................................................................................................

NUMBER OF AIM SECURITIES IN ISSUE
As of 09 March 2022, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were:

Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
54,933,000
14.44%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,331,396
6.66%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,386,275
5.36%

Interactive Investor
19,790,573
5.20%

Atul Unadkat
17,350,145
4.38%

Rathbone Nominees Limited
16,095,276
4.24%

Amati AIM VCT plc
14,282,652
3.76%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.49%



.....................................
NUMBER OF AIM SECURITIES IN ISSUE
As of 18 August 2021, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were:


Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
54,933,000
14.44%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,331,396
6.66%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,386,275
5.36%

Interactive Investor
19,790,573
5.20%

Rathbone Nominees Limited
16,122,338
4.24%

Amati AIM VCT plc
14,282,652
3.76%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.49%

...................


Home
SECURITIES INFORMATION


NUMBER OF AIM SECURITIES IN ISSUE
As of 21 February 2021, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were:


Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
58,333,000
15.34%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,452,709
6.69%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,421,575
5.37%

Amati AIM VCT plc
16,937,750
4.45%

Rathbone Nominees Limited
16,156,166
4.25%

Interactive Investor
15,405,978
4.05%

HSBC Global Custody Nominee (UK) Limited
14,015,588
3.69%


NUMBER OF AIM SECURITIES IN ISSUE
As of 21 August 2020, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were:


BGF Investment Management Limited
58,333,000
15.34%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Hargreaves Lansdown
30,276,493
7.96%

Gresham House Asset Management Limited
27,845,445
7.32%

Canaccord Genuity Group Inc
22,684,000
5.94%

JM Finn Nominees Limited
21,774,435
5.72%

Amati AIM VCT plc
16,937,750
4.45%

Rathbone Nominees Limited
16,246,373
4.27%

HSBC Global Custody Nominee (UK) Limited
14,007,734
3.68%

Interactive Investor
12,992,073
3.42%


supersonico - 03 Dec 2022 - 07:03:11 - 13502 of 14935 Eden Research - EDEN
Atul keeps buying.

As of 30 September 2022, the number of shares in issue was 380,858,607.
As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were:

Number of shares % of the issued ordinary share capital

BGF Investment Management Limited
53,733,000
14.11%

Sipcam Oxon S.p.A.
37,614,830
9.88%

Hargreaves Lansdown
29,839,285
7.83%

Gresham House Asset Management Limited
27,845,445
7.31%


Canaccord Genuity Group Inc
22,584,000
5.93%

Interactive Investor
20,027,730
5.26%

JM Finn Nominees Limited
19,277,362
5.06%

Atul Unadkat
17,545,098
4.61%

Rathbone Nominees Limited
15,708,999
4.12%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.48%


......................................................................................................................

NUMBER OF AIM SECURITIES IN ISSUE
As of 09 March 2022, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were:

Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
54,933,000
14.44%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,331,396
6.66%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,386,275
5.36%

Interactive Investor
19,790,573
5.20%

Atul Unadkat
17,350,145
4.38%

Rathbone Nominees Limited
16,095,276
4.24%

Amati AIM VCT plc
14,282,652
3.76%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.49%



.....................................
NUMBER OF AIM SECURITIES IN ISSUE
As of 18 August 2021, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were:


Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
54,933,000
14.44%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,331,396
6.66%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,386,275
5.36%

Interactive Investor
19,790,573
5.20%

Rathbone Nominees Limited
16,122,338
4.24%

Amati AIM VCT plc
14,282,652
3.76%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.49%

...................


Home
SECURITIES INFORMATION


NUMBER OF AIM SECURITIES IN ISSUE
As of 21 February 2021, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were:


Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
58,333,000
15.34%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,452,709
6.69%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,421,575
5.37%

Amati AIM VCT plc
16,937,750
4.45%

Rathbone Nominees Limited
16,156,166
4.25%

Interactive Investor
15,405,978
4.05%

HSBC Global Custody Nominee (UK) Limited
14,015,588
3.69%


NUMBER OF AIM SECURITIES IN ISSUE
As of 21 August 2020, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were:


BGF Investment Management Limited
58,333,000
15.34%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Hargreaves Lansdown
30,276,493
7.96%

Gresham House Asset Management Limited
27,845,445
7.32%

Canaccord Genuity Group Inc
22,684,000
5.94%

JM Finn Nominees Limited
21,774,435
5.72%

Amati AIM VCT plc
16,937,750
4.45%

Rathbone Nominees Limited
16,246,373
4.27%

HSBC Global Custody Nominee (UK) Limited
14,007,734
3.68%

Interactive Investor
12,992,073
3.42%


supersonico - 05 Oct 2022 - 08:52:18 - 13219 of 14935 Eden Research - EDEN
Selling yes..but it's a dribble which has been bought by Atul etal.

As of 30 September 2022, the number of shares in issue was 380,858,607.
As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were:

Number of shares % of the issued ordinary share capital

BGF Investment Management Limited
53,733,000
14.11%

Sipcam Oxon S.p.A.
37,614,830
9.88%

Hargreaves Lansdown
29,839,285
7.83%

Gresham House Asset Management Limited
27,845,445
7.31%


Canaccord Genuity Group Inc
22,584,000
5.93%

Interactive Investor
20,027,730
5.26%

JM Finn Nominees Limited
19,277,362
5.06%

Atul Unadkat
17,545,098
4.61%

Rathbone Nominees Limited
15,708,999
4.12%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.48%


......................................................................................................................

NUMBER OF AIM SECURITIES IN ISSUE
As of 09 March 2022, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were:

Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
54,933,000
14.44%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,331,396
6.66%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,386,275
5.36%

Interactive Investor
19,790,573
5.20%

Atul Unadkat
17,350,145
4.38%

Rathbone Nominees Limited
16,095,276
4.24%

Amati AIM VCT plc
14,282,652
3.76%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.49%



.....................................
NUMBER OF AIM SECURITIES IN ISSUE
As of 18 August 2021, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were:


Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
54,933,000
14.44%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,331,396
6.66%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,386,275
5.36%

Interactive Investor
19,790,573
5.20%

Rathbone Nominees Limited
16,122,338
4.24%

Amati AIM VCT plc
14,282,652
3.76%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.49%

...................


Home
SECURITIES INFORMATION


NUMBER OF AIM SECURITIES IN ISSUE
As of 21 February 2021, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were:


Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
58,333,000
15.34%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,452,709
6.69%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,421,575
5.37%

Amati AIM VCT plc
16,937,750
4.45%

Rathbone Nominees Limited
16,156,166
4.25%

Interactive Investor
15,405,978
4.05%

HSBC Global Custody Nominee (UK) Limited
14,015,588
3.69%


NUMBER OF AIM SECURITIES IN ISSUE
As of 21 August 2020, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were:


BGF Investment Management Limited
58,333,000
15.34%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Hargreaves Lansdown
30,276,493
7.96%

Gresham House Asset Management Limited
27,845,445
7.32%

Canaccord Genuity Group Inc
22,684,000
5.94%

JM Finn Nominees Limited
21,774,435
5.72%

Amati AIM VCT plc
16,937,750
4.45%

Rathbone Nominees Limited
16,246,373
4.27%

HSBC Global Custody Nominee (UK) Limited
14,007,734
3.68%

Interactive Investor
12,992,073
3.42%


1

[ravenna23] 22/1/2024 05:35

FRC re Accounts year end 2019Eden ResearchTransactions with associateWe asked for more information about the group's sale of geraniol to its associate and the group's acquisition of an intangible asset from the associate. We also queried the existence of, and accounting for, any unrealised gain or loss (in applying the equity method) arising from such transactions.The company explained that it had reconsidered the guidance in IFRS 15 'Revenue from Contracts with Customers' in relation to its arrangement with the associate for the sale of geraniol. As a result, the company acknowledged that the group accounts (in addition to recognising the group's share of the result of the associate through the normal equity accounting) should have recognised revenue based upon the margin it was entitled to receive from the associate's sale of geraniol instead of on a gross basis. Consequently, the company agreed to restate comparative amounts in the following year's income statement accordingly. As the change affected a primary statement, we asked the company to disclose the fact that the matter had come to its attention as result of our enquiry.